A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System
NCT ID: NCT01368679
Last Updated: 2014-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The benefits and risks of the study should be explained before any specific test or procedure of the study. The written consent must be obtained from the patient. No action specifies the study should be performed while the patient has not signed the form of consent.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The mortality and comorbidity were associated with significant surgical repair of AAAs, particularly in elderly patients with multiple medical problems. Surgical complications were mainly associated with the surgical incision, comorbidity presented by the patient, changes cardiopulmonary and problems related to clotting of the patient. The postoperative complications included bleeding, renal failure, paraplegy, and the need for prolonged ventilatory support. The literature shows that mortality rates for elective surgery is 0-6.1%, with 2.7% as average.
Due to the risks and complexities inherent in surgical procedures, various devices and alternative methods have been proposed to treat aneurysms. The method most used today is the implantation of stents through a delivery system. This method is defined as minimally invasive to dispense the need for opening the abdominal cavity through large incisions, and use a remote access (common femoral artery or external iliac) to introduce and deploy the device via an endovascular route.
With technological progress have been developed many devices, all with similar characteristics, which are currently used in different countries. Numerous devices are currently used to treat aneurysms.
Over the past 10 years, were developed and approved new stents, however, despite the advances that have represented the use of minimally invasive devices, and evidence of improvement in indices of morbidity and mortality in the first six months, there is still a need to improve results, since the long-term endovascular treatment is equal to the conventional surgical treatment. With the technological devices you can improve your long-term performance and obviate the need for dissection of the femoral vessels using thinner delivery devices that allow percutaneous introduction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endoprothesis Scitech
The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.
The delivery system is done by linear drive or screw diameters greater than 30mm
Endoprothesis Implantation
stent implantation in the abdominal artery using endovascular
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endoprothesis Implantation
stent implantation in the abdominal artery using endovascular
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Concordance of the patient through the end of a written consent form approved by the local Ethics Committee;
3. Proximal colon with the following characteristics: the intima to intima diameter of 16 to 30mm; Length of the proximal neck greater than 8mm angulation of the aorta justarenal less than or equal to 60 degrees.
4. Iliac axes: the distal neck length greater than 10mm; the intima to intima diameter between 7 and 20mm.
5. Present at least one of the following:
* Aneurysm diameter \> 4.5 cm,
* Aneurysm that has increased in size from 0.5cm in the last six months,
* aneurysm with maximum diameter greater at least one and half times the expected normal aortic diameter.
6. Patient who has access to the iliac or femoral artery for stent implantation in the abdominal aorta.
7. The patient is able to meet the follow-up examination in 30 days, 180 days and 360 days.
Exclusion Criteria
2. Patients with dissecting aneurysm.
3. Patients with acute symptoms of ruptured aneurysm.
4. Patient with acute vascular injury.
5. Patients referred for emergency treatment.
6. Patients with tortuous iliac / femoral exceedingly difficult to access.
7. Patient with abdominal aortic dissection.
8. Patient with congenital anomalies after the placement of the stent will cause the main blood flow occlusion.
9. The patient with unstable angina.
10. Morbid obesity, or other clinical conditions that severely inhibit visualization of the USG of the aorta.
11. Patient with a history of connective tissue disease syndrome (eg, Marfan or Ehler's-Danlos syndrome).
12. Patient with a history of bleeding with the refusal of blood transfusions.
13. Patients with known hypersensitivity to the means of anticoagulation or contrast.
14. Patient with chronic renal failure (creatinine increase greater than or equal to 2.0 mg / dL).
15. Mycotic aneurysm or a systemic infection activates
16. Patient with a known allergy or intolerance to the components of these devices.
17. Patient is currently participating in another clinical trial investigating whether the device or drug.
18. Patient with other medical observations, social or psychological, according to the investigator's opinion, impossible to receive this treatment, the procedures and continuation of the pre and post-treatment.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Scitech Produtos Medicos Ltda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Álvaro Razuk, Medicine
Role: PRINCIPAL_INVESTIGATOR
Irmandade da Santa Casa de Misericórdia de São Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Caridade
São Francisco do Sul, Santa Catarina, Brazil
Irmandade da Santa Casa de Misericórdia de São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Site sponsor
Site about the location that will be done the study. Location where the principal investigator works.
National Information System on Ethics in Research involving Human
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Scitech 003
Identifier Type: -
Identifier Source: org_study_id